Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 25 or more amino acid residues in defined sequence
Reexamination Certificate
2006-03-28
2006-03-28
Stucker, Jeffrey (Department: 1648)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
25 or more amino acid residues in defined sequence
C530S325000, C530S326000, C530S350000, C530S807000, C530S825000, C435S007100, C435S007200, C435S005000
Reexamination Certificate
active
07019111
ABSTRACT:
The present invention generally relates to compositions and methods for preventing and treating human diseases including, but not limited to, pathogens such as bacteria, yeast, parasites, fungus, viruses, and cancer. More specifically, embodiments described herein concern the manufacture and use of ligand/receptor specificity exchangers, which redirect existing antibodies in a subject to receptors present on pathogens.
REFERENCES:
patent: 4169138 (1979-09-01), Jonsson
patent: 4376110 (1983-03-01), David et al.
patent: 4471058 (1984-09-01), Smith et al.
patent: 4486530 (1984-12-01), David et al.
patent: 4589881 (1986-05-01), Pierschbacher et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5091513 (1992-02-01), Huston et al.
patent: 5175096 (1992-12-01), Hook et al.
patent: 5189015 (1993-02-01), Hook et al.
patent: 5196510 (1993-03-01), Rodwell et al.
patent: 5260189 (1993-11-01), Formoso et al.
patent: 5320951 (1994-06-01), Hook et al.
patent: 5416021 (1995-05-01), Hook et al.
patent: 5440014 (1995-08-01), Hook et al.
patent: 5561049 (1996-10-01), Vold et al.
patent: 5571511 (1996-11-01), Fischer
patent: 5571514 (1996-11-01), Hook et al.
patent: 5582975 (1996-12-01), Milliman
patent: 5601830 (1997-02-01), Su et al.
patent: 5627263 (1997-05-01), Ruoslahti et al.
patent: 5652217 (1997-07-01), Hook et al.
patent: 5700928 (1997-12-01), Hodgson et al.
patent: 5714332 (1998-02-01), Lussow et al.
patent: 5766857 (1998-06-01), Ruoslahti et al.
patent: 5766951 (1998-06-01), Brown
patent: 5770208 (1998-06-01), Fattom et al.
patent: 5770702 (1998-06-01), Hook et al.
patent: 5776712 (1998-07-01), Kuusela et al.
patent: 5789549 (1998-08-01), Hook et al.
patent: 5840846 (1998-11-01), Hook et al.
patent: 5843774 (1998-12-01), Ginsberg
patent: 5846536 (1998-12-01), Bissell et al.
patent: 5866541 (1999-02-01), Hook et al.
patent: 5869232 (1999-02-01), Sällberg
patent: 5888738 (1999-03-01), Hendry
patent: 5922548 (1999-07-01), Lussow et al.
patent: 5929220 (1999-07-01), Tong et al.
patent: 5939273 (1999-08-01), Lussow et al.
patent: 5942606 (1999-08-01), Lal et al.
patent: 5955078 (1999-09-01), Burnham et al.
patent: 5980908 (1999-11-01), Hook et al.
patent: 5981274 (1999-11-01), Tyrell et al.
patent: 6008341 (1999-12-01), Foster et al.
patent: 6030613 (2000-02-01), Blumberg et al.
patent: 6040137 (2000-03-01), Sällberg
patent: 6066648 (2000-05-01), Duggan et al.
patent: 6077677 (2000-06-01), Hodgson et al.
patent: 6086875 (2000-07-01), Blumberg et al.
patent: 6086895 (2000-07-01), Hook et al.
patent: 6087330 (2000-07-01), Kogan et al.
patent: 6090388 (2000-07-01), Wang
patent: 6090944 (2000-07-01), Hutchinson
patent: 6093539 (2000-07-01), Maddon et al.
patent: 6245985 (2001-06-01), Sasaki et al.
patent: 6417324 (2002-07-01), Sällberg
patent: 6485726 (2002-11-01), Blumberg et al.
patent: 2002/0025513 (2002-02-01), Sällberg
patent: 2002/0058247 (2002-05-01), Sällberg
patent: 2003/0021789 (2003-01-01), Xu et al.
patent: 2003/0044418 (2003-03-01), Davis et al.
patent: 0 182 546 (1986-05-01), None
patent: 0 508 427 (1992-10-01), None
patent: 9020798 (1997-01-01), None
patent: WO 93/15210 (1993-08-01), None
patent: WO 93/17044 (1993-09-01), None
patent: WO 94/13804 (1994-06-01), None
patent: WO 95/08577 (1995-03-01), None
patent: WO 95/29938 (1995-11-01), None
patent: WO 98/03543 (1998-01-01), None
patent: WO 98/31389 (1998-07-01), None
patent: WO 98/43677 (1998-10-01), None
patent: WO 99/27109 (1999-06-01), None
patent: WO 99/61041 (1999-12-01), None
patent: WO 00/26385 (2000-05-01), None
patent: WO 95/22249 (2000-05-01), None
patent: WO 00/66621 (2000-11-01), None
patent: WO 01/81421 (2001-11-01), None
patent: WO 01/82546 (2001-11-01), None
patent: WO 02/24887 (2002-03-01), None
Barbas et al., “Assembly of combinatorial antibody libraries on phage surfaces: The gene III site,”Proc Natl Acad Sci USA, 88:7978-7982, (1991).
Bianchi et al., “Chemical Synthesis of a Designed Beta-Protein through the Flow-Polyamide Method,”Int J Pept Protein Res, 41(4):385-393 (1993).
Bianchi et al., “Afinity Purification of a Difficult-Sequence Protein: Implications for the Inclusion of Capping in Synthetic Protocols,”Int J Pept Protein Res, 42(1):93-96 (1993).
Bichko et al., “Epitopes recognized by antibodies to denatured core protein of hepatitis B virus,”Mol. Immunol., 30(3):221-231, (1993).
Brett et al., “The invasin protein of Yersinia spp. Provides co-stimulatory activity to human T cells thorugh interaction with beta 1 integrins,”Eur. J. Immunol., 23(7):1608-1614 (1993).
Cello, J, et al., “Identification of group-common linear epitopes in structural and nonstructural proteins of enteroviruses by using synthetic peptides,”J. Clin. Microbiol., 31(4):911-916 (1993).
Chien et al., “Identification of group-common linear epitopes in structural and nonstructural proteins of enteroviruses by using synthetic peptides,”Proc Natl Acad Sci USA, 88:9578-9582 (1991).
Cohen, J., et al., “Ligand binding to the cell surface receptor for reovirus type 3 stimulates galactocerebroside expression by developing oligodendrocytes,”Proc. Natl. Acad. Sci. USA, 87(13):4922-4926 (1990).
Colberre-Garapin et al., “A new dominant hybrid selective marker for higher eukaryotic cells,”J. Molecular Biology, 150:1 (1981).
Database Genseq 'Online! Oct. 21, 1991, Asahi Chemical Ind. KK: “L-chain variable region of plasminogen activator antibody” XP002183673, Accession AAP61027 (published in JP11729000).
Database Genseq 'Online! Jan. 8, 1993, Clonatec SA: “Hepatitis B irus HBc antigen II,” XP002183674, Accession AAR25272 (published in EP494825).
Database Genseq 'Online! Jul. 1, 1993, Cytel Corp: “Cytotoxic T-lymphocyte inducing peptide 802.03.” XP002183675, Accession AAR33488.
Database WPI, Section Ch., Week 199713, Derwent Publications Ltd., London, GB: Class B04, AN 1997-140911, XP002183678 & JP 09 020798 A (Asahi Kasei Kogyo KK) Jan. 21, 1997, abstract.
Database Patent_PRT 'Online! Mar. 21, 2001, Eurodiagnostica AB: “Sequance 9 from Patent W)0116163” XP002183677, Accession AX 090806.
Database Genseq 'Online! Jul. 31, 2000, Yeda Res & Dev Co Ltd: “Murine anti-Pab-421 IDI-1 mAb heavy chain CDR based Peptide IDI-H1”, XP002183676, Accession AAY70799 (published in WO0023082).
Doolittle et al., “The amino Acid Sequence of the alpha-Chain of Human Fibrinogen.”Nature, 280(5722):464-468, (1979).
Felding-Habermann et al., “Role of β3 Integrins in Melanoma cell Adhesion to Activated Platelets under Flow,”J. Biol. Chem., 271(10):5892-5900 (1996).
Flock, “Extracellular-Matrix-Binding Proteins as Targets for the Prevention of Staphylococcus Aureus Infections,”Molecular Medicine Today, 5(12):532-537 (1999).
Ganem, “Hepadnaviridae and their replication,”Fields Virology, Third Ed., pp. 2703-2705 (1996).
GenCore Sequence Alignment of Sequence ID No: 16 with the L-chain variable region of plasminogen activator antibody of JP61172900-A, Ashi Chemical Ind. KK. (Apr. 8, 1986) ID NO: p. 61027.
Grabowska et al., “Identification of type-specific domains within glycoprotein G of herpes simplex virus type 2 (HSV-2) recognized by the majority of patients infected with HSV-2, but not by those infected with HSV-1,”Journal of General Virology, 80(pt.7):1789-1798 (1999).
Greenspan et al., Nature Biotechnology, 7:936-937 (1999).
Haseltine, “Replication and Pathogenesis of the AIDS Virus,”Journal of Acquired Immune Deficiency Syndromes, 1(3):217-240 and 231-236, (1988).
Henschen et al., “Amino acid sequence of human fibrin. Preliminary note on the Completion of the β-Chain Sequence,”Z. Physiol. Chem., 358(12):1643-1646 (1977).
Holliger et al., “Diabodies': Small Bivalent and Bispecific Antibody Fragments,”Proc Natl Acad Sci USA, 90(14):6444-6448, (1993).
Huse et al., “Generation of a large combinatorial library of the
Knobbe Martens Olson & Bear LLP
Stucker Jeffrey
Tripep AB
LandOfFree
Glycosylated ligand/receptor specificity exchangers specific... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Glycosylated ligand/receptor specificity exchangers specific..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glycosylated ligand/receptor specificity exchangers specific... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3601533